Live Analyst Rating Changes 18449 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yanan Zhu
WF

Yanan Zhu

Wells Fargo
Wall Street Analyst
★★☆☆☆
#2750
on 13Foresight · ranked by our own returns
43%
Success Rate
+5.0%
Average Return
15 of 35 calls profitable · -4.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 43% of Yanan Zhu's ratings turned a profit when each position was held for 1 year — averaging +5.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

82 Buy 25 Hold 0 Sell
Yanan's Stock Coverage 28 ratings · 2026-08-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CRSP
Crispr Therapeutics AG
 Aug 05, 2026 HOLD Buy
+45.0% avg upside
41 analysts
$75.00
42.94% Upside
 +0.0% ·
SYRE
Spyre Therapeutics
 Aug 04, 2026 BUY Strong Buy
-12.6% avg upside
23 analysts
$115.00
10.12% Upside
 -2.2% ·
RNA
Atrium Therapeutics, Inc.
 Jul 15, 2026 BUY Strong Buy
+189.8% avg upside
4 analysts
$25.00
112.94% Upside
 -1.5% ·
PHVS
Pharvaris
 Jul 15, 2026 BUY Strong Buy
+38.1% avg upside
15 analysts
$55.00
64.62% Upside
 -8.6% ·
IONS
Ionis Pharmaceuticals
 Jul 10, 2026 BUY Strong Buy
+46.0% avg upside
43 analysts
$100.00
84.60% Upside
 -5.5% ·
SGMOQ
Sangamo Therapeutics
 Jun 25, 2026 HOLD Buy
+11841.7% avg upside
16 analysts
 — +75.0% ·
ENGN
enGene Holdings
 Jun 15, 2026 HOLD Buy
+456.8% avg upside
13 analysts
$2.00
11.11% Upside
 -1.7% ·
BEAM
Beam Therapeutics
 Jun 04, 2026 BUY Strong Buy
+92.3% avg upside
25 analysts
$70.00
158.51% Upside
 -17.6% ·
NTLA
Intellia Therapeutics
 May 12, 2026 HOLD Buy
+247.9% avg upside
37 analysts
$15.00
36.81% Upside
 -20.3% ·
MGX
Metagenomi, Inc.
 May 11, 2026 BUY Strong Buy
+622.8% avg upside
8 analysts
$9.00
640.72% Upside
 -11.8% ·
CYTK
Cytokinetics
 May 07, 2026 BUY Strong Buy
+12.9% avg upside
36 analysts
$105.00
33.13% Upside
 +5.9% ·
SRPT
Sarepta Therapeutics
 May 07, 2026 BUY Buy
+271.2% avg upside
49 analysts
$38.00
138.59% Upside
 -28.6% ·
ONC
BeOne Medicines
 May 07, 2026 BUY Strong Buy
+8.8% avg upside
28 analysts
$400.00
22.21% Upside
 +3.3% ·
TSHA
Taysha Gene Therapies
 May 07, 2026 BUY Strong Buy
+117.4% avg upside
21 analysts
$11.00
70.23% Upside
 -4.7% ·
NAMS
NewAmsterdam Pharma Company
 Apr 02, 2026 BUY Strong Buy
+75.8% avg upside
19 analysts
$45.00
64.06% Upside
 -16.9% ·
EDIT
Editas Medicine
 Mar 10, 2026 HOLD Buy
+395.6% avg upside
33 analysts
$4.00
45.41% Upside
 -2.3% ·
QURE
uniQure
 Mar 09, 2026 BUY Strong Buy
+34.1% avg upside
29 analysts
$60.00
35.72% Upside
 +142.1% ·
ARCT
Arcturus Therapeutics
 Mar 04, 2026 BUY Buy
+373.2% avg upside
36 analysts
$20.00
219.56% Upside
 -17.4% ·
IOVA
Iovance Biotherapeutics
 Feb 25, 2026 BUY Buy
+193.4% avg upside
24 analysts
$14.00
222.61% Upside
 +6.3% ·
AUTL
Autolus Therapeutics
 Jan 14, 2026 BUY Strong Buy
+464.2% avg upside
16 analysts
$5.00
163.25% Upside
 +6.3% ·
CLLS
Cellectis SA
 Jan 13, 2026 HOLD Strong Buy
+619.5% avg upside
16 analysts
$4.00
43.35% Upside
 -32.9% ·
FATE
Fate Therapeutics
 Jan 05, 2026 HOLD Buy
+362.9% avg upside
31 analysts
$2.50
3.88% Downside
 +146.5% ·
ADAPY
Adaptimmune Therapeutics
 May 14, 2025 HOLD Buy
+8354.5% avg upside
10 analysts
$1.00
3536.35% Upside
 -92.7% ·
AFMDQ
Affimed
 May 14, 2025 HOLD Buy
+14226263.6% avg upside
16 analysts
$0.10
99899.98% Upside
 · ·
VYGR
Voyager Therapeutics
 May 06, 2025 BUY Strong Buy
+360.6% avg upside
23 analysts
$10.00
222.51% Upside
 +28.3% ·
TECX
Tectonic Therapeutic
 May 16, 2024 HOLD Strong Buy
+91.0% avg upside
24 analysts
 — +25.8% ·
TCRT
Alaunos Therapeutics
 Aug 16, 2023 HOLD Buy
+650.4% avg upside
13 analysts
$30.00
1385.07% Upside
 -90.5% ·
ARGX
Argenx Se
 Feb 02, 2021 HOLD Strong Buy
-9.9% avg upside
47 analysts
$326.00
62.39% Downside
 -14.4% ·
🔒 23 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yanan Zhu — Frequently Asked Questions
How accurate are Yanan Zhu's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Yanan's ratings were profitable over a one-year hold, with an average return of +4.7% per rating, or -5.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yanan ranked on 13Foresight?
Yanan Zhu is currently ranked #2750 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yanan cover?
Yanan most recently has ratings on CRSP, SYRE, RNA, PHVS, IONS, SGMOQ, ENGN, BEAM, NTLA, MGX, CYTK, SRPT and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.